Key takeaways
- Retatrutide (LY3437943) is a single peptide that activates the GIP, GLP-1 and glucagon receptors; Eli Lilly is developing it and funded every trial on this page.
- It is investigational and not approved anywhere: the TGA says no comparable international regulator has approved it, and the MHRA says it is not authorised in the UK.
- The first phase 3 obesity trials, TRIUMPH-1 and TRIUMPH-2, were published in NEJM and The Lancet on 29 September 2026; Lilly plans to submit for US approval in the first quarter of 2027.
- FDA says retatrutide cannot be used in compounding under federal law, and its August 2026 warning letters list products sold online as retatrutide, including as “GLP-3”, among unapproved new drugs.
- In November 2026 the TGA’s laboratory found that tested products from one brand, sold as retatrutide, held less than their labels stated, with significant variation between samples.
01Retatrutide at a glance
The short version, dated 18 November 2026.
| Question | Retatrutide |
|---|---|
| What it is | A single peptide that activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon. Lilly calls it a triple hormone receptor agonist. |
| Other names | LY3437943, its development code. FDA warning letters record sellers listing it as “GLP-3 RT” and “GLP-3R”; no PubMed title or abstract on retatrutide uses “GLP-3” (18 Nov 2026). |
| Developer | Eli Lilly and Company, which funded every trial on this page. |
| Evidence tier | T1, investigational: randomised, placebo-controlled trials of Lilly’s product, published from 2022 to 2026. |
| Phase 3 studies | ClinicalTrials.gov lists 14, all sponsored by Lilly: 5 completed, 9 active or recruiting. |
| United States | Not approved. FDA says it “cannot be used in compounding under federal law”. Lilly plans to submit an application for approval in the first quarter of 2027. |
| United Kingdom | MHRA, 15 Oct 2026: “Retatrutide has not been authorised for use in the UK.” |
| Australia | TGA, 5 Nov 2026: not approved “by the TGA or any comparable international regulator”. |
02What retatrutide is, and where “GLP-3” comes from
Retatrutide is one peptide that activates three hormone receptors: the receptors for GIP and GLP-1, and the receptor for glucagon. That is why the papers call it a triple agonist. Early human results were published in 2022 under its code, LY3437943, including a 12-week phase 1b trial of 72 adults with type 2 diabetes, randomised against placebo, whose primary outcome was safety and tolerability.
“GLP-3” is not a name the research uses for retatrutide: no PubMed title or abstract on retatrutide uses it (18 Nov 2026), and the trial papers we cite call it retatrutide or LY3437943. The label comes from sellers. FDA warning letters dated 24 August 2026 record products listed as “Retatrutide (GLP-3 RT)”, “GLP-3 RT (Retatrutide) Research Peptide” and “GLP-3R”, sold alongside products listed as “Semaglutide (GLP-1 SEM)” and “Tirzepatide (GLP-2 TRZ)”.
03What the phase 3 trials measured
Lilly’s phase 3 obesity programme is called TRIUMPH. Its first results papers appeared between September and November 2026.
Each trial below was randomised, placebo-controlled and funded by Lilly. We list who took part and what each trial set out to measure. We do not repeat efficacy figures for a drug that is not approved anywhere.
| Trial and paper | Who took part | Length | Primary endpoint |
|---|---|---|---|
| Phase 2 · NEJM, 2023 | 338 adults with a body-mass index (BMI) of 30 or more, or 27 to under 30 with a weight-related condition | 48 weeks | Percentage change in body weight at 24 weeks |
| TRIUMPH-1 · NEJM, online 29 Sep 2026 | 2,339 adults with obesity and without diabetes, with sub-studies of 574 people with knee osteoarthritis and 243 with obstructive sleep apnoea | 80 weeks | Percentage change in body weight; in the sub-studies, a knee-pain score (WOMAC) and the apnoea–hypopnoea index, a count of pauses and shallow breaths per hour of sleep |
| TRIUMPH-2 · The Lancet, online 29 Sep 2026 | 1,152 adults with type 2 diabetes and a BMI of 27 or more, at 92 centres in eight countries | 80 weeks | Percentage change in body weight |
| TRIUMPH-4 · NEJM, online 8 Nov 2026 | 445 adults without diabetes, with painful knee osteoarthritis and a BMI of at least 27; the same paper reports TRIUMPH-1’s knee sub-study | 68 weeks | WOMAC pain score and percentage change in body weight |
Adverse events. These describe Lilly’s product under trial conditions. In the phase 2 trial the most common adverse events were gastrointestinal, mostly mild to moderate, and heart rate rose, peaking at 24 weeks. In TRIUMPH-2, gastrointestinal events, low blood pressure and dysaesthesia (altered skin sensation) were more frequent than with placebo, and stopping treatment for good because of adverse events or death was more frequent in two of the three retatrutide groups. In the knee osteoarthritis trials, serious adverse events were more common with retatrutide than with placebo.
None of this describes material sold outside the trials, which has not been through them. How to read safety data like this: side effects, documented vs unknown.
04Is retatrutide approved?
No. As of 18 November 2026 it is not approved in any country.
United States. Lilly said on 29 September 2026 that it “plans to submit a Biologics License Application (BLA) in Q1 2027” to FDA. A submission asks FDA to review the evidence; it is not an approval. FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says retatrutide and cagrilintide “cannot be used in compounding under federal law” and “are not components of FDA-approved drugs and have not been found safe and effective for any condition”.
United Kingdom. The MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK” and that “Products being sold as retatrutide outside legitimate clinical trials are being supplied illegally and could pose serious risks to public health.” More: are peptides legal in the UK?
Australia. The TGA wrote on 5 November 2026 that retatrutide “is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator”, and that any retatrutide product obtained outside a clinical trial “could be counterfeit”. More: are peptides legal in Australia?
Elsewhere. A JAMA news feature of 9 October 2026 on retatrutide and a second pipeline drug, zenagamtide, noted that “neither therapy has been approved by any regulatory authority in the world”.
05Why products sold online as retatrutide are not the trial drug
Every trial above tested Lilly’s product. Material sold online under the same name has not been through those trials, and regulators in the US, the UK and Australia have acted on it.
FDA. Warning letters dated 24 August 2026 to four online sellers listed their retatrutide products, labelled for research use and sold under names including “GLP-3 RT” and “GLP-3R”, among unapproved new drugs. FDA’s GLP-1 page says the agency has warned companies that “illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.
MHRA. See its 15 October 2026 statement above: products sold as retatrutide outside legitimate clinical trials “are being supplied illegally”.
TGA. In November 2026 the TGA’s laboratory tested products from one brand sold as “Retatrutide 10 mg” and found they “contained less retatrutide than stated on the label, with significant variation between samples”. The TGA concluded that consumers cannot rely on these labels to know what substance, or what amount, a product contains. Other cases: contamination and mislabeling.
A lab report can show what one tested sample contained: its identity, amount and purity. It cannot turn that sample into the product Lilly tested, or into an approved medicine. How identity is checked: mass spectrometry explained.
06What we don’t know
- Whether any regulator will approve retatrutide, or for what. Lilly plans its US submission for the first quarter of 2027.
- Its effect on heart and kidney outcomes. TRIUMPH-Outcomes, planned for about 10,000 adults with obesity, is listed as active, not recruiting, with primary completion expected in February 2029 (NCT06383390).
- The full results of TRIUMPH-3, in 1,946 adults with obesity and cardiovascular disease. ClinicalTrials.gov lists it as completed (NCT05882045); we found no journal paper (PubMed, 18 Nov 2026).
- What any vial sold online contains. A lab report shows what the tested sample held, and the TGA found one brand’s labels did not match the contents.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.